We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Tosoh To Increase Production Capacity of Separation and Purification Media

Tosoh To Increase Production Capacity of Separation and Purification Media content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Separation and purification media are key products of Tosoh’s Bioscience Division and are used in the purification process of biopharmaceutical manufacturing as well as other processes. One of the critical applications is the purification of antibody-derived molecules. Besides this still growing market, demand for biopharmaceuticals is expanding to gene therapies, RNA-based vaccines and drugs, and other modalities. The oligonucleotide drug market is growing rapidly, leading to active investment in new development and manufacturing, and Tosoh provides high-resolution resins with superior productivity for such therapeutics. To meet the increased demand for all those different applications, Tosoh will increase production capacity by approximately 70 % to ensure a stable supply.

The company continues to invest aggressively not only in separation and purification media but also in pre-packed columns for purification (SkillPakTM) and continuous chromatography systems (Octave®(*)). Tosoh aims to become a total solution provider in the biopharmaceutical manufacturing process.

The expansion plan will allow the company to keep pace with growing demand. Together with the augmentation of its related product lineup, Tosoh will continue to expand its business.

*: “Octave” is the registered trademark of Tosoh Bioscience Wisconsin, Inc. (formerly Semba Biosciences, Inc.) in the United States.